Provided by Tiger Trade Technology Pte. Ltd.

MediciNova

1.50
-0.0709-4.52%
Volume:34.00K
Turnover:50.93K
Market Cap:73.68M
PE:-6.85
High:1.58
Open:1.57
Low:1.43
Close:1.57
52wk High:1.96
52wk Low:1.17
Shares:49.15M
Float Shares:43.50M
Volume Ratio:1.06
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2188
EPS(LYR):-0.2445
ROE:-25.56%
ROA:-16.41%
PB:1.98
PE(LYR):-6.13

Loading ...

3 Promising Penny Stocks With Over $50M Market Cap

Simply Wall St.
·
Yesterday

MediciNova CEO Iwaki Base Salary Rises to $690,246 Under New Employment Agreement

Reuters
·
Aug 19

Jason McCarthy Reiterates Buy on MediciNova, Maintains $6 Price Target Ahead of Key ALS and Metabolic Disease Readouts

TIPRANKS
·
Aug 15

MediciNova Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

MediciNova Inc Expected to Post a Loss of 6 Cents a Share - Earnings Preview

Reuters
·
Aug 08

MediciNova: Differentiated NAFLD/MASH Profile and Complementary APOC3 Positioning Support Unchanged $6 Target and Buy Rating

TIPRANKS
·
Jul 24

Analysts Offer Insights on Healthcare Companies: Medicinova (MNOV), Legend Biotech (LEGN) and AngioDynamics (ANGO)

TIPRANKS
·
Jul 16

Medicinova Announces Patient Enrollment Milestone Achieved in Seanobi Study Expanded-access-program Evaluating Mn‑166 (ibudilast) in ALS Patients

THOMSON REUTERS
·
Jul 15

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

GlobeNewswire
·
Jul 15

Analyst Reiterates Buy on MediciNova as Advancing Pipeline and Upcoming ALS Catalysts Support Unchanged $6 Price Target

TIPRANKS
·
Jul 02

Medicinova Says US Patent Office Allows Ibudilast–anti-pd-1 Combo Claims for Glioblastoma Treatment

Reuters
·
Jun 30

Medicinova CEO Provides Shareholder Update

THOMSON REUTERS
·
Jun 30

MediciNova CEO Provides Shareholder Update

GlobeNewswire
·
Jun 30

Medicinova Stockholders Reject Proposal to Boost Authorized Common Shares to 247 Million

Reuters
·
Jun 25

MediciNova Granted US Patent Notice of Allowance for Ibudilast Combination to Treat Brain Cancer

MT Newswires Live
·
Jun 08

Medicinova - Patent Expected to Expire No Earlier Than September 2042

THOMSON REUTERS
·
Jun 08

Medicinova - Receives U.S. Patent Notice for Mn-166 With Anti-Pd-1 in Glioblastoma

THOMSON REUTERS
·
Jun 08

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

GlobeNewswire
·
Jun 08

Analysts’ Top Healthcare Picks: Coherus Biosciences (CHRS), Medicinova (MNOV)

TIPRANKS
·
May 29

Analyst Initiates Buy on MediciNova, Citing Pivotal Tipelukast and Ibudilast Catalysts to Support $10 Price Target

TIPRANKS
·
May 28